Novo Nordisk, the maker of obesity and diabetes drugs Wegovy and Ozempic, files a lawsuit against its US rival Eli Lilly. Novo Nordisk alleges that Eli Lilly is engaging in false advertising through its marketing comparing the two companies’ products. According to reporting that describes the claims, Novo Nordisk argues that Eli Lilly’s ads rely on misleading or incorrect data when presenting comparisons between weight-loss treatments and diabetes products.
The case focuses on how the companies’ medicines are portrayed in advertising rather than on any specific product recall or safety finding. Novo Nordisk’s position is that the comparative claims in Eli Lilly’s campaign are not supported by appropriate data or are presented in a way that gives a misleading impression. The outlets reporting the matter also describe the dispute as part of the companies’ broader rivalry in the fast-growing obesity and weight-management drug market.
No court outcome is reported in the available summaries, and the details of any requested remedies or specific advertising statements are not included here.
